Contents

Ab	brevia	tions us	ed	iii	
Grading of recommendations					
List of tables					
Ex	ecutive	e summ	ary of recommendations	viii	
Re	Resources				
1	Purpose and scope				
2	Definitions of overweight and obesity			2	
3	Why is this guideline focusing on contraception and raised BMI needed?			2	
4	An overview of data on fertility, sexual activity, contraceptive use and unintended pregnancy among women with raised BMI			3	
5	Suitability of contraceptive methods for women who are overweight or women with obesity			4	
	5.1	Intrauterine contraception (IUC)		6	
		5.1.1	IUC effectiveness	6	
		5.1.2	IUC safety	7	
		5.1.3	Weight gain with IUC	8	
		5.1.4	Health benefits of IUC	8	
		5.1.5	Practical considerations with IUC	8	
	5.2	Progestogen-only implants (IMP)		8	
		5.2.1	Implant effectiveness	9	
		5.2.2	Implant safety	11	
		5.2.3	Weight gain with implants	11	
		5.2.4	Health benefits of implants	11	
		5.2.5	Practical considerations with implants	11	
	5.3	Progestogen-only injectable		12	
		5.3.1	DMPA effectiveness	12	
		5.3.2	DMPA safety	13	
		5.3.3	Weight gain with DMPA	14	
		5.3.4	Health benefits of DMPA	15	
		5.3.5	Practical considerations with DMPA	15	

FSF	RH g	uidelin	e: Overweight, Obesity and Contraception	
F	SRH 5.4	Progestogen-only pill (POP)		
	0.1	5.4.1	POP effectiveness	15 15
		5.4.2	POP safety	16
		5.4.3	Weight gain with POP	10
		5.4.4	Health benefits of POP	17
	5.5	Combined hormonal contraception (CHC)		17
		5.5.1	CHC effectiveness	17
		5.5.2	CHC safety	20
		5.5.3	Weight gain with CHC	22
		5.5.4	Health benefits of CHC	22
	5.6	Barrier methods of contraception		22
		5.6.1	Barrier method effectiveness	22
		5.6.2	Barrier method safety	22
	5.7	Fertility	/ awareness methods	23
	5.8	Emergency contraception (EC)		23
		5.8.1	Cu-IUD	23
		5.8.2	Oral EC	23
	5.9	Female surgical sterilisation		25
		5.9.1	Effectiveness and safety	25
6	Contraception and weight management treatment		n and weight management treatment	25
	6.1	Weight-loss medication and contraception		25
		6.1.1	Orlistat	26
		6.1.2	Liraglutide	26
		6.1.3	Naltrexone/buproprion	27
		6.1.4	Laxatives	27
	6.2	Weight	t-loss surgery and contraception	27
		6.2.1	Background	27

- 6.2.2 UKMEC information on bariatric surgery 28 6.2.3 Effectiveness and safety of contraception after bariatric surgery 29 6.2.4 31
 - Contraception before bariatric surgery

7 Approach to issues of weight in contraceptive consultations	VFSRH 32	
Recommendations for future research		
Considerations for implementation of this guideline		
Useful links		
References	34	
Appendix 1: FSRH Clinical Guideline Development Process		
Questions for continuing professional development		
Auditable outcomes		
Comments and feedback on published guideline		

FSRH guideline: Overweight, Obesity and Contraception

Information Box

Title	Overweight, Obesity and Contraception
Author/Publisher	Faculty of Sexual & Reproductive Healthcare
Publication date	April 2019
Superseded document	None
Review date	April 2024
Available online	www.fsrh.org/documents/fsrh-clinical-guidance-overweight-and-obesity-april-2019